发布求助
文献互助 智能选刊 最新文献

Annals of Oncology最新文献

筛选
英文 中文
European Oncology Nursing Society (EONS)
IF 56.7 1区 医学
Annals of Oncology Pub Date : 2024-09-01 DOI: 10.1016/S0923-7534(24)03811-0
{"title":"European Oncology Nursing Society (EONS)","authors":"","doi":"10.1016/S0923-7534(24)03811-0","DOIUrl":"10.1016/S0923-7534(24)03811-0","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":null,"pages":null},"PeriodicalIF":56.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0923753424038110/pdfft?md5=03983dec8d8b561e1f3b4497988e9251&pid=1-s2.0-S0923753424038110-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142238186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
1O The somatic mutation landscape of the normal and malignant pancreas
IF 56.7 1区 医学
Annals of Oncology Pub Date : 2024-09-01 DOI: 10.1016/j.annonc.2024.08.011
{"title":"1O The somatic mutation landscape of the normal and malignant pancreas","authors":"","doi":"10.1016/j.annonc.2024.08.011","DOIUrl":"10.1016/j.annonc.2024.08.011","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":null,"pages":null},"PeriodicalIF":56.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0923753424015308/pdfft?md5=4bde63d35f9cec999261778a19eb61ae&pid=1-s2.0-S0923753424015308-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142238189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
75MO Atlas of tertiary lymphoid structures in solid tumors: Genomic features and prediction of response to immunotherapy
IF 56.7 1区 医学
Annals of Oncology Pub Date : 2024-09-01 DOI: 10.1016/j.annonc.2024.08.083
{"title":"75MO Atlas of tertiary lymphoid structures in solid tumors: Genomic features and prediction of response to immunotherapy","authors":"","doi":"10.1016/j.annonc.2024.08.083","DOIUrl":"10.1016/j.annonc.2024.08.083","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":null,"pages":null},"PeriodicalIF":56.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0923753424016028/pdfft?md5=b587db97cdd5ec7064804b91c3c0f67d&pid=1-s2.0-S0923753424016028-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142238863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
90P Clonal haematopoiesis of indeterminate potential (CHIP) might mislead interpretation of ATM and CHEK2 alterations detected on liquid biopsies
IF 56.7 1区 医学
Annals of Oncology Pub Date : 2024-09-01 DOI: 10.1016/j.annonc.2024.08.098
{"title":"90P Clonal haematopoiesis of indeterminate potential (CHIP) might mislead interpretation of ATM and CHEK2 alterations detected on liquid biopsies","authors":"","doi":"10.1016/j.annonc.2024.08.098","DOIUrl":"10.1016/j.annonc.2024.08.098","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":null,"pages":null},"PeriodicalIF":56.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S092375342401617X/pdfft?md5=57a3f8b14d055232eaba9da65f23f22a&pid=1-s2.0-S092375342401617X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142242603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
44P Chemo-immunotherapy combination of mFOLFOX6, bevacizumab and atezolizumab after first-line therapy for advanced biliary tract cancer: The COMBATBIL imCORE trial
IF 56.7 1区 医学
Annals of Oncology Pub Date : 2024-09-01 DOI: 10.1016/j.annonc.2024.08.053
{"title":"44P Chemo-immunotherapy combination of mFOLFOX6, bevacizumab and atezolizumab after first-line therapy for advanced biliary tract cancer: The COMBATBIL imCORE trial","authors":"","doi":"10.1016/j.annonc.2024.08.053","DOIUrl":"10.1016/j.annonc.2024.08.053","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":null,"pages":null},"PeriodicalIF":56.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0923753424015722/pdfft?md5=884fd053d2092fa15fca29935778bbbc&pid=1-s2.0-S0923753424015722-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142243058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Volume 35 | Supplement 2 | September 2024
IF 56.7 1区 医学
Annals of Oncology Pub Date : 2024-09-01 DOI: 10.1016/S0923-7534(24)03809-2
{"title":"Volume 35 | Supplement 2 | September 2024","authors":"","doi":"10.1016/S0923-7534(24)03809-2","DOIUrl":"10.1016/S0923-7534(24)03809-2","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":null,"pages":null},"PeriodicalIF":56.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0923753424038092/pdfft?md5=2af8554843738c1ab44674e9b71c4c7a&pid=1-s2.0-S0923753424038092-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142242965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
79P Comprehensive genomic profiling provides patients access to novel matched therapies in a diverse real-world cohort of advanced lung cancer patients
IF 56.7 1区 医学
Annals of Oncology Pub Date : 2024-09-01 DOI: 10.1016/j.annonc.2024.08.087
{"title":"79P Comprehensive genomic profiling provides patients access to novel matched therapies in a diverse real-world cohort of advanced lung cancer patients","authors":"","doi":"10.1016/j.annonc.2024.08.087","DOIUrl":"10.1016/j.annonc.2024.08.087","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":null,"pages":null},"PeriodicalIF":56.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0923753424016065/pdfft?md5=c8844c83103e219087b5048b7b520455&pid=1-s2.0-S0923753424016065-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142244023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
3P Metabolic reprogramming induced by KEAP1 mutation in NSCLC
IF 56.7 1区 医学
Annals of Oncology Pub Date : 2024-09-01 DOI: 10.1016/j.annonc.2024.08.013
{"title":"3P Metabolic reprogramming induced by KEAP1 mutation in NSCLC","authors":"","doi":"10.1016/j.annonc.2024.08.013","DOIUrl":"10.1016/j.annonc.2024.08.013","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":null,"pages":null},"PeriodicalIF":56.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0923753424015321/pdfft?md5=5abd881957af5d0d4c6fe6368aa3c71f&pid=1-s2.0-S0923753424015321-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142242128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
71MO Clinical and biomarker analyses of intratumoral CD40 agonist sotigalimab in combination with pembrolizumab in metastatic melanoma: A phase I/II trial
IF 56.7 1区 医学
Annals of Oncology Pub Date : 2024-09-01 DOI: 10.1016/j.annonc.2024.08.079
{"title":"71MO Clinical and biomarker analyses of intratumoral CD40 agonist sotigalimab in combination with pembrolizumab in metastatic melanoma: A phase I/II trial","authors":"","doi":"10.1016/j.annonc.2024.08.079","DOIUrl":"10.1016/j.annonc.2024.08.079","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":null,"pages":null},"PeriodicalIF":56.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0923753424015989/pdfft?md5=1cad8e54e3cf12d43fc050e3bcf7c590&pid=1-s2.0-S0923753424015989-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142238045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
55P Subsequent anticancer therapy (SAT) analysis from 3-year follow-up of the phase III TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in biliary tract cancer (BTC)
IF 56.7 1区 医学
Annals of Oncology Pub Date : 2024-09-01 DOI: 10.1016/j.annonc.2024.08.064
{"title":"55P Subsequent anticancer therapy (SAT) analysis from 3-year follow-up of the phase III TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in biliary tract cancer (BTC)","authors":"","doi":"10.1016/j.annonc.2024.08.064","DOIUrl":"10.1016/j.annonc.2024.08.064","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":null,"pages":null},"PeriodicalIF":56.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0923753424015837/pdfft?md5=f719a124a902018b61c85d4082c3a974&pid=1-s2.0-S0923753424015837-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142238531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信